FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

This study is testing a combination treatment for advanced melanoma (a serious type of skin cancer). It uses focused ultrasound (sound waves) to destroy tumor tissue, followed by an injection of a drug (polyICLC) directly into the tumor to activate the immune system. The goal is to see if this combination, alongside the immune checkpoint therapy you are already receiving, can shrink tumors more effectively. **You may be eligible if...** - You are 18 or older with advanced melanoma planned for surgery - The tumor can be seen on ultrasound and is accessible for treatment - You are already receiving immunotherapy (checkpoint blockade therapy) - You are generally able to carry out daily activities **You may NOT be eligible if...** - You received radiation therapy, certain immune-suppressing drugs, or chemotherapy within the past 4 weeks - You have active, serious infections - You have severe heart disease (Class III or IV) - You have HIV or active Hepatitis B or C (unless on stable treatment with undetectable levels) - You are pregnant or breastfeeding - You have a known alcohol or drug addiction and are actively using Talk to your doctor to see if this trial is right for you.